Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS). [PDF]
POCUS JArumugam S, Kalagara H.
europepmc +1 more source
Comment on: GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region. [PDF]
Saudi Med Jeuropepmc +1 more source
Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD
Diabetes & Metabolism Journalopenaire +3 more sources
GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.
JAMA Intern MedHuang T +7 more
europepmc +1 more source
Letter: Methodological Concerns Regarding GLP-1RA Effects on MASLD Outcomes
Clinical and Molecular Hepatologyopenaire +1 more source
Related searches:
GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
Current Hypertension Reviews, 2021Background:Diabetes is a chronic disease with high complexity that demands strategic medical care with a multifactorial risk-reduction approach. Over the past decade, the treatment of type 2 diabetes mellitus (T2DM) has entirely changed. One of the paradigm changes has been the arrival of new drugs that reduce cardiovascular risk beyond the reduction ...
Aschner Pablo +3 more
openaire +2 more sources
The GLP-1RAs: From Evolution to Revolution
The Singapore Family Physician, 2022Research on incretin hormones has advanced considerably over the past few decades. Although the initial molecule – glucose-dependent insulinotropic polypeptide – failed to stimulate insulin secretion in patients with type 2 diabetes, it led to the discovery of glucagon-like peptide 1 (GLP-1). As GLP-1 impacts on various tissues and cells throughout the
openaire +1 more source
GLP-1RA based therapies in the young and old
Current Opinion in Endocrinology, Diabetes & ObesityPurpose of review Obesity is recognized as a “gateway” chronic, progressive disease of dysfunctional adipocytes. Glucagon-like peptide-1 receptor agonist-based therapies (GLP1BTs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with/without glucose-dependent insulinotropic polypeptide (GIP), have demonstrated ...
Georgia, Rigas +2 more
openaire +2 more sources
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Current Diabetes Reports, 2018In addition to their effects on glycemic control, two specific classes of relatively new anti-diabetic drugs, namely the sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated reduced rates of major adverse cardiovascular events (MACE) in subjects with type 2 diabetes (T2D) at high ...
Dorrin Zarrin, Khat, Mansoor, Husain
openaire +2 more sources